Stenocare Valuation
Is STENO undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of STENO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate STENO's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate STENO's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for STENO?
Key metric: As STENO is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is STENO's PS Ratio? | |
|---|---|
| PS Ratio | 20x |
| Sales | DKK 2.23m |
| Market Cap | DKK 44.76m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 21.7x |
| Enterprise Value/EBITDA | -4x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does STENO's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 13.9x | ||
MPCI Memphis Pharmaceuticals & Chemical Industries | 0.3x | n/a | ج.م324.1m |
ALID Allied | 54.5x | n/a | US$5.4m |
6566 Chuang Yi Biotech | 0.7x | n/a | NT$176.5m |
STHZ StateHouse Holdings | 0.05x | n/a | CA$7.7m |
STENO Stenocare | 20x | n/a | DKK 44.8m |
Price-To-Sales vs Peers: STENO is expensive based on its Price-To-Sales Ratio (20x) compared to the peer average (18.3x).
Price to Sales Ratio vs Industry
How does STENO's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?
| 23 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 23 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: STENO is expensive based on its Price-To-Sales Ratio (20x) compared to the European Pharmaceuticals industry average (2.9x).
Price to Sales Ratio vs Fair Ratio
What is STENO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 20x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate STENO's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.